pubmed_ids
stringlengths 41
6.9k
| questions
stringlengths 13
215
| ground_truth
stringlengths 2
7.79k
|
|---|---|---|
http://www.ncbi.nlm.nih.gov/pubmed/25957348 | Describe the INSPEcT R package | INSPEcT is a computational tool to infer mRNA synthesis, processing and degradation dynamics from RNA- and 4sU-seq time course experiments.INSPEcT is an R package for the integrative analysis of RNA- and 4sU-seq data to study the dynamics of transcriptional regulation. INSPEcT provides gene-level quantification of these rates, and a modeling framework to identify which of these regulatory processes are most likely to explain the observed mRNA and pre-mRNA concentrations. Software performance is tested on a synthetic dataset, instrumental to guide the choice of the modeling parameters and the experimental design.INSPEcT is an R package for the integrative analysis of RNA- and 4sU-seq data to study the dynamics of transcriptional regulation. INSPECT provides gene-level quantification of these rates, and a modeling framework to identify which of these regulatory processes are most likely to explain the observed mRNA and pre-mRNA concentrations. Software performance is tested on a synthetic dataset, instrumental to guide the choice of the modeling parameters and the experimental design.INSPEcT is an R package for the integrative analysis of RNA- and 4sU-seq data to study the dynamics of transcriptional regulation. In addition, it provides gene-level quantification of these rates, and a modeling framework to identify which of these regulatory processes are most likely to explain the observed mRNA and pre-mRNA concentrations.INSPEcT is an R package for the integrative analysis of RNA- and 4sU-seq data to study the dynamics of transcriptional regulation.InSPEcT is an R package for the integrative analysis of RNA-seq data to study the dynamics of transcriptional regulation.INSPEcT is an R package for the integrative analysis of RNA- and 4sU-seq data to study the dynamics of transcriptional regulation. To graphically inspect the resulting networks, the package contains a visualization tool, which allows for the direct network manipulation and access of node and link information. INSPecT-GUI is freely available within the R/Bioconductor package INSPECT at http://bioconductor.org/packages/INSPECAT/.INSPEcT is an R package for the integrative analysis of RNA- and 4sU-seq data to study the dynamics of transcriptional regulation. In particular, it provides a modeling framework to identify which of these regulatory processes are most likely to explain the observed mRNA and pre-mRNA concentrations. Software performance is tested on a synthetic dataset, instrumental to guide the choice of the modeling parameters and the experimental design. |
http://www.ncbi.nlm.nih.gov/pubmed/30575804,http://www.ncbi.nlm.nih.gov/pubmed/29273685,http://www.ncbi.nlm.nih.gov/pubmed/31377284,http://www.ncbi.nlm.nih.gov/pubmed/31813786,http://www.ncbi.nlm.nih.gov/pubmed/30385883,http://www.ncbi.nlm.nih.gov/pubmed/25105999,http://www.ncbi.nlm.nih.gov/pubmed/26087256,http://www.ncbi.nlm.nih.gov/pubmed/33221815,http://www.ncbi.nlm.nih.gov/pubmed/32088116,http://www.ncbi.nlm.nih.gov/pubmed/32040069,http://www.ncbi.nlm.nih.gov/pubmed/32059832,http://www.ncbi.nlm.nih.gov/pubmed/32157641,http://www.ncbi.nlm.nih.gov/pubmed/31814726,http://www.ncbi.nlm.nih.gov/pubmed/30215690,http://www.ncbi.nlm.nih.gov/pubmed/32429706,http://www.ncbi.nlm.nih.gov/pubmed/26361263,http://www.ncbi.nlm.nih.gov/pubmed/32707005,http://www.ncbi.nlm.nih.gov/pubmed/31971679,http://www.ncbi.nlm.nih.gov/pubmed/31356255,http://www.ncbi.nlm.nih.gov/pubmed/24878056,http://www.ncbi.nlm.nih.gov/pubmed/28467880,http://www.ncbi.nlm.nih.gov/pubmed/29744034,http://www.ncbi.nlm.nih.gov/pubmed/32795835,http://www.ncbi.nlm.nih.gov/pubmed/33237667 | Which molecule is targeted by Teprotumumab? | Teprotumumab is a human monoclonal antibody that targets IGF-1R. It can be used for treatment of thyroid eye disease. |
http://www.ncbi.nlm.nih.gov/pubmed/33193411,http://www.ncbi.nlm.nih.gov/pubmed/30431097,http://www.ncbi.nlm.nih.gov/pubmed/31664825,http://www.ncbi.nlm.nih.gov/pubmed/31519749,http://www.ncbi.nlm.nih.gov/pubmed/32345636 | Which protein is encoded by the protein APOBEC3C? | The gene APOBEC3C codes for: apolipoprotein B mRNA editing enzyme catalytic polypeptide-like 3C |
http://www.ncbi.nlm.nih.gov/pubmed/27928026,http://www.ncbi.nlm.nih.gov/pubmed/29430654,http://www.ncbi.nlm.nih.gov/pubmed/29056570,http://www.ncbi.nlm.nih.gov/pubmed/28625644,http://www.ncbi.nlm.nih.gov/pubmed/26898616 | Does AZD3759 cross the blood brain barrier? | AZD3759 is a novel EGFR tyrosine kinase inhibitor with high capability to penetrate the blood-brain barrier.AZD3759 is an EGFR tyrosine kinase inhibitors (TKIs) with excellent blood-brain barrier (BBB) penetration.Yes, AZD3759 cross the blood brain barrier. |
http://www.ncbi.nlm.nih.gov/pubmed/20232936,http://www.ncbi.nlm.nih.gov/pubmed/19620965,http://www.ncbi.nlm.nih.gov/pubmed/21551148,http://www.ncbi.nlm.nih.gov/pubmed/22435808,http://www.ncbi.nlm.nih.gov/pubmed/26305225,http://www.ncbi.nlm.nih.gov/pubmed/17038564,http://www.ncbi.nlm.nih.gov/pubmed/21206756,http://www.ncbi.nlm.nih.gov/pubmed/30113318 | What is the major sequence determinant for nucleosome positioning? | G+C content is the primary determinant of MNase-derived nucleosome occupancy. |
http://www.ncbi.nlm.nih.gov/pubmed/32227647 | Which is the primary enzyme metabolizing esomeprazole? | Esomeprazole is primarily metabolized by CYP2C19. |
http://www.ncbi.nlm.nih.gov/pubmed/33122718,http://www.ncbi.nlm.nih.gov/pubmed/26836588,http://www.ncbi.nlm.nih.gov/pubmed/32081864,http://www.ncbi.nlm.nih.gov/pubmed/32941940 | Which factors contribute to the risk of very-early-onset inflammatory bowel disease? | Somalatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease, particularly atrial fibrillation and dysregulation of transcphenne muscular dystrophy, as well as other genetic variation, in the early phase of disease.Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease (VEO-IBD).Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease. Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype associated with a spectrum of rare Mendelian disorders.Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype associated with a spectrum of rare Mendelian disorders. Somatic mosaicism and common genetic variation contribute to the risk of this disease.Very-early-onset inflammatory bowel disease (VEO-IBD) is a heterogeneous phenotype associated with a spectrum of rare Mendelian disorders including Crohn's disease, depression and cocaine addiction. Somatic mosaicism and common genetic variation contribute to the risk of IBD. |
http://www.ncbi.nlm.nih.gov/pubmed/32078672,http://www.ncbi.nlm.nih.gov/pubmed/32905674 | What disease is treated with BIVV001? | BIVV001 fusion protein has been developed as Factor VIII replacement therapy for hemophilia A |
http://www.ncbi.nlm.nih.gov/pubmed/25490878,http://www.ncbi.nlm.nih.gov/pubmed/28849097,http://www.ncbi.nlm.nih.gov/pubmed/27647250 | What is the mode of action of Thiazovivin? | Thiazovivin is a selective small molecule that directly targets Rho-associated kinase (ROCK) and increases expression of pluripotency factors. |
http://www.ncbi.nlm.nih.gov/pubmed/17477348,http://www.ncbi.nlm.nih.gov/pubmed/17611545,http://www.ncbi.nlm.nih.gov/pubmed/28374668,http://www.ncbi.nlm.nih.gov/pubmed/15682788,http://www.ncbi.nlm.nih.gov/pubmed/1524841,http://www.ncbi.nlm.nih.gov/pubmed/12915472,http://www.ncbi.nlm.nih.gov/pubmed/11438711,http://www.ncbi.nlm.nih.gov/pubmed/25136351,http://www.ncbi.nlm.nih.gov/pubmed/7828232,http://www.ncbi.nlm.nih.gov/pubmed/27194855,http://www.ncbi.nlm.nih.gov/pubmed/23542155,http://www.ncbi.nlm.nih.gov/pubmed/21416650,http://www.ncbi.nlm.nih.gov/pubmed/187357 | Explain the association between Barr bodies (nuclear inclusions) and the X chromosome? | Barr body is an inactivated X chromosome in the normal female somatic cell.A Barr body (named after discoverer Murray Barr) is an inactive X chromosome in a cell with more than one X chromosome, rendered inactive in a process called lyonization, in species with XY sex-determination (including humans).Transcriptional inactivation of one X chromosome in mammalian female somatic cells leads to condensation of the inactive X chromosome into the heterochromatic sex chromatin, or Barr body.Barr body is an inactivated X chromosome in the normal female somatic cell |
http://www.ncbi.nlm.nih.gov/pubmed/24909324,http://www.ncbi.nlm.nih.gov/pubmed/10809665,http://www.ncbi.nlm.nih.gov/pubmed/28287392,http://www.ncbi.nlm.nih.gov/pubmed/26335634,http://www.ncbi.nlm.nih.gov/pubmed/26335633,http://www.ncbi.nlm.nih.gov/pubmed/23560912,http://www.ncbi.nlm.nih.gov/pubmed/30518940,http://www.ncbi.nlm.nih.gov/pubmed/28676122,http://www.ncbi.nlm.nih.gov/pubmed/30993896,http://www.ncbi.nlm.nih.gov/pubmed/27879204,http://www.ncbi.nlm.nih.gov/pubmed/28671979,http://www.ncbi.nlm.nih.gov/pubmed/27599465,http://www.ncbi.nlm.nih.gov/pubmed/22247430 | Is the zelda transcription factor a chromatin remodeller? | During developmental transition, the zygotic genome is largely transcriptionally quiescent and undergoes significant chromatin remodeling. In Drosophila, the DNA-binding protein Zelda (also known as Vielfaltig) is required for this transition and for transcriptional activation of the zygotic genome. Zelda is differentially required for chromatin accessibility, transcription factor binding, and gene expression in the early Drosophila embryo. Zelda overcomes the high intrinsic nucleosome barrier at enhancers during Drosophila zygotic genome activation. Early enhancers are characterized by an intrinsically high nucleosome barrier. Zelda tackles this nucleosome barrier through local depletion of nucleosomes with the effect being dependent on the number and position of zelda(zld) motifs.Yes, it is known as a chromatin remodeling factor.Yes, the zebrafish transcription factor Zelda is a chromatin remodeling factor.Yes, it is known as a transcription factor for a chromatin remodeling factor.Yes, the zelda transcription factor is a chromatin remodller.Zelda is differentially required for chromatin accessibility, transcription factor binding, and gene expression in the early Drosophila embryo. Zelda is essential for hundreds of regions of open chromatin. Zelda binds cis-regulatory elements (TAGteam heptamers), making chromatin accessible for gene transcription.This Zelda-mediated chromatin accessibility facilitates transcription-factor recruitment and early gene expression. |
http://www.ncbi.nlm.nih.gov/pubmed/32029306 | What is the effect of the alleles CYP2C19*2 and CYP2C19*3 on CYP2C19 function? | The CYP2C19*2 and CYP2C19*3 alleles of CYP2C19 are associated with loss-of-function (LOF). |
http://www.ncbi.nlm.nih.gov/pubmed/32005800 | Describe Full Spectrum of Intolerance to Loss-of-function (FUSIL) | Full Spectrum of Intolerance to Loss-of-function (FUSIL) is a cross-species gene classification across the full spectrum of mutations in genes of unknown function. FUSIL has been proposed as a method to identify potentially pathogenic variants in genes not previously associated with rare diseases.The identification of causal variants in sequencing studies remains a considerable challenge that can be partially addressed by new gene-specific knowledge. By integrating measures of how essential a gene is to supporting life, as inferred from viability and phenotyping screens performed on knockout mice by the International Mouse Phenotyping Consortium and essentiality screens carried out on human cell lines, a cross-species gene classification across the Full Spectrum of Intolerance to Loss-of-function (FUSIL) was proposed. Genes in five mutually exclusive FUSIL categories have differing biological properties. Most notably, Mendelian disease genes, particularly those associated with developmental disorders, are highly overrepresented among genes non-essential for cell survival but required for organism development.The FUSIL is the Full Spectrum of Intolerance to Loss-of-function (FUSIL). It's the full spectrum of genes that are not essential for cell survival, but essential for organism development.Full Spectrum of Intolerance to Loss-of-function (FUSIL) is a cross-species gene classification across the full spectrum of genes in five mutually exclusive categories have differing biological properties. FUSIL is proposed as an efficient approach for disease gene discovery.Full Spectrum of Intolerance to Loss-of-function (FUSIL) is a cross-species gene classification across the full spectrum of essential and non-essential genes. FUSIL is an efficient approach for disease gene discovery. |
http://www.ncbi.nlm.nih.gov/pubmed/31776899 | Is capmatinib effective for glioblastoma? | No. Combination of capmatinib buparlisib resulted in no clear activity in patients with recurrent PTEN-deficient glioblastoma. |
http://www.ncbi.nlm.nih.gov/pubmed/33151599,http://www.ncbi.nlm.nih.gov/pubmed/31862270,http://www.ncbi.nlm.nih.gov/pubmed/31936187,http://www.ncbi.nlm.nih.gov/pubmed/32627752 | Are there antimicrobial proteins in royal jelly? | Yes,
Jelleines, isolated as novel antibacterial peptides from the Royal Jelly (RJ) of bees, exhibit broad-spectrum protection against microbial infections. |
http://www.ncbi.nlm.nih.gov/pubmed/12046269,http://www.ncbi.nlm.nih.gov/pubmed/27087232,http://www.ncbi.nlm.nih.gov/pubmed/30546257,http://www.ncbi.nlm.nih.gov/pubmed/26952518,http://www.ncbi.nlm.nih.gov/pubmed/10418432,http://www.ncbi.nlm.nih.gov/pubmed/29068423,http://www.ncbi.nlm.nih.gov/pubmed/11261244 | What are the years of the initiation and completion of the Human Genome project? | The Human Genome Project was initiated in 1990 and completed in 2003.The Human Genome Project (HGP) was initiated in 1990, and the completion of the genome project was in 2003. |
http://www.ncbi.nlm.nih.gov/pubmed/28273065,http://www.ncbi.nlm.nih.gov/pubmed/30150754,http://www.ncbi.nlm.nih.gov/pubmed/29148971,http://www.ncbi.nlm.nih.gov/pubmed/29887377,http://www.ncbi.nlm.nih.gov/pubmed/30109602,http://www.ncbi.nlm.nih.gov/pubmed/31848476,http://www.ncbi.nlm.nih.gov/pubmed/24051548,http://www.ncbi.nlm.nih.gov/pubmed/29401453,http://www.ncbi.nlm.nih.gov/pubmed/25887659 | Which methods infer 3D genome structure without proximity ligation? | SPRITE is a method that enables genome-wide detection of higher-order interactions within the nucleus.
Transposase-mediated analysis of chromatin looping (Trac-looping) for simultaneous detection of multiscale genome-wide chromatin interactions among regulatory elements and chromatin accessibility.
Genome architecture mapping (GAM) can be used for measuring chromatin contacts and other features of three-dimensional chromatin topology on the basis of sequencing DNA from a large collection of thin nuclear sections.To investigate three-dimensional (3D) genome organization in prokaryotic and eukaryotic cells, three main strategies are employed, namely nuclear proximity ligation-based methods, imaging tools (such as fluorescence in situ hybridization (FISH) and its derivatives), and computational/visualization methods.Proximity ligation assays commonly known as chromosome conformation capture (3C) and 3C based methodologies (e.g., GCC, HiC and ChIA-Pet) are increasingly being incorporated into empirical studies to investigate the role that three-dimensional genome structure plays in the regulation of phenotype. By combining 3C and high-throughput sequencing, the Hi-C method reveals genome-wide interactions within topological domains and global genome structure as a whole. Here we report a genome-wide method, genome architecture mapping (GAM), for measuring chromatin contacts and other features of three-dimensional chromatin topology on the basis of sequencing DNA from a large collection of thin nuclear sections. We describe a genome architecture assay, tethered multiple 3C (TM3C), that maps genome-wide chromatin contacts via a simple protocol of restriction enzyme digestion and religation of fragments upon agarose gel beads followed by paired-end sequencing. Using SPRITE, we recapitulate known structures identified by proximity ligation and identify additional interactions occurring across larger distances, including two hubs of inter-chromosomal interactions that are arranged around the nucleolus and nuclear speckles. We now report transposase-mediated analysis of chromatin looping (Trac-looping) for simultaneous detection of multiscale genome-wide chromatin interactions among regulatory elements and chromatin accessibility.Proximity ligation assays commonly known as chromosome conformation capture (3C) and 3C based methodologies (e.g., GCC, HiC and ChIA-Pet) are increasingly being incorporated into empirical studies to investigate the role that three-dimensional genome structure plays in the regulation of phenotype. By combining 3C and high-throughput sequencing, the Hi-C method reveals genome-wide interactions within topological domains and global genome structure as a whole. Here we report a genome-wide method, genome architecture mapping (GAM), for measuring chromatin contacts and other features of three-dimensional chromatin topology on the basis of sequencing DNA from a large collection of thin nuclear sections. We describe a genome architecture assay, tethered multiple 3C (TM3C), that maps genome-wide chromatin contacts via a simple protocol of restriction enzyme digestion and religation of fragments upon agarose gel beads followed by paired-end sequencing. Using SPRITE, we recapitulate known structures identified by proximity ligation and identify additional interactions occurring across larger distances, including two hubs of inter-chromosomal interactions that are arranged around the nucleolus and nuclear speckles. |
http://www.ncbi.nlm.nih.gov/pubmed/32504034 | How many genes are screened by the FoundationOne companion diagnostic? | FoundationOne CDx comprises a 324-gene panel. |
http://www.ncbi.nlm.nih.gov/pubmed/27320920 | Interaction of WDR5 with which gene has a critical role in pancreatic cancer? | Mechanistically, WDR5 functions to sustain proper execution of DNA replication in pancreatic ductal adenocarcinoma (PDAC) cells, as previously suggested by replication stress studies involving MLL1, and c-Myc, also found to interact with WDR5. It was indeed demonstrated that interaction with c-Myc is critical for this function.WDR5 is a core member of the COMPASS histone H3 Lys4 (H3K4) MLL (1-4) methyltransferase complex, as a top tumor maintenance hit required across multiple human and mouse tumors. Mechanistically, WDR5 functions to sustain proper execution of DNA replication in PDAC cells, as previously suggested by replication stress studies involving MLL1, and c-Myc, also found to interact with WDRWDR5 has been implicated in cancer for its role in the COMPASS complex and its interaction with Myc. Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance. The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferationInteraction of WDR5 with WDR4 and c-Myc is critical for the development of pancreatic cancer. |
http://www.ncbi.nlm.nih.gov/pubmed/31838406,http://www.ncbi.nlm.nih.gov/pubmed/24672280 | Can thiotepa be recommended for treatment of osteosarcoma? | No. Thiotepa did not improve survival of patients with osteosarcoma and therefore can not be recommended for treatment of osteosarcoma. |
http://www.ncbi.nlm.nih.gov/pubmed/27079701,http://www.ncbi.nlm.nih.gov/pubmed/24380647,http://www.ncbi.nlm.nih.gov/pubmed/18710591,http://www.ncbi.nlm.nih.gov/pubmed/18565216 | What is known about aberrant proteolytic activity in disease? | Research into Alzheimer's disease pathology and treatment has often focused on presenilin proteins. These proteins provide the key catalytic activity of the γ-secretase complex in the cleavage of amyloid-β precursor protein and resultant amyloid tangle deposition. Over the last 25 years, screening novel drugs to control this aberrant proteolytic activity has yet to identify effective treatments for the disease.
Others are human skin disorders where proteolytic pathways are dysregulated. |
http://www.ncbi.nlm.nih.gov/pubmed/22147573,http://www.ncbi.nlm.nih.gov/pubmed/33198930,http://www.ncbi.nlm.nih.gov/pubmed/10665958,http://www.ncbi.nlm.nih.gov/pubmed/24642292,http://www.ncbi.nlm.nih.gov/pubmed/8920722,http://www.ncbi.nlm.nih.gov/pubmed/9639687,http://www.ncbi.nlm.nih.gov/pubmed/10886022,http://www.ncbi.nlm.nih.gov/pubmed/12736429,http://www.ncbi.nlm.nih.gov/pubmed/16621680,http://www.ncbi.nlm.nih.gov/pubmed/16751800,http://www.ncbi.nlm.nih.gov/pubmed/19563911,http://www.ncbi.nlm.nih.gov/pubmed/15450422,http://www.ncbi.nlm.nih.gov/pubmed/18083062,http://www.ncbi.nlm.nih.gov/pubmed/11357715,http://www.ncbi.nlm.nih.gov/pubmed/21237724,http://www.ncbi.nlm.nih.gov/pubmed/12116376,http://www.ncbi.nlm.nih.gov/pubmed/8676929,http://www.ncbi.nlm.nih.gov/pubmed/10432996,http://www.ncbi.nlm.nih.gov/pubmed/26861493,http://www.ncbi.nlm.nih.gov/pubmed/15784691,http://www.ncbi.nlm.nih.gov/pubmed/19712750,http://www.ncbi.nlm.nih.gov/pubmed/11024477,http://www.ncbi.nlm.nih.gov/pubmed/18979316,http://www.ncbi.nlm.nih.gov/pubmed/11287293,http://www.ncbi.nlm.nih.gov/pubmed/24361396 | Does a comet assay measure radiation induced mutations? | Yes. The comet assay is frequently used to measure DNA damage in individual cells.Evaluation of primary DNA-damage is one way to identify potential genotoxic agents and for this purpose the Comet assay has, for the last decades, been used to monitor DNA single strand and double strand breaks in individual cellsThe comet assay is frequently used to measure DNA damage in individual cells following exposure to mutagens such as ionizing radiation.Yes, a comet assay measures radiation-induced mutations in DNA. |
http://www.ncbi.nlm.nih.gov/pubmed/30017589,http://www.ncbi.nlm.nih.gov/pubmed/28143843,http://www.ncbi.nlm.nih.gov/pubmed/25349449,http://www.ncbi.nlm.nih.gov/pubmed/29359419 | What is formative pluripotency? | Formative pluripotency features a gene regulatory network switch from the nave state. Two phases of pluripotency, called nave and primed, have previously been described.Two phases of pluripotency, called naïve and primed, have previously been described. The transcription factor network that governs the naive state is rapidly dismantled prior to upregulation of lineage specification markers, creating an intermediate state that is called formative pluripotency.Formative pluripotency features a gene regulatory network switch from the na ve state and comprises capacitation of enhancers, signaling pathways and epigenetic machinery in order to install competence for lineage specification.Formative pluripotency is an intermediate stage in the developmental continuum. It's a bit of a misnomer. The term "formative" comes from the word "formal" which is used to refer to an intermediate state that isn't fully formed.Formative pluripotency features a gene regulatory network switch from the naïve state and comprises capacitation of enhancers, signaling pathways and epigenetic machinery in order to install competence for lineage specification. Here, we discuss an intermediate stage of pluripotency that we term "formative". Notably, these studies show that the transcription factor network that governs the naive state is rapidly dismantled prior to upregulation of lineage specification markers, creating an intermediate state that we term formative pluripotency. In this Hypothesis article, a third phase, called formative pluripotency, is proposed to exist as part of a developmental continuum between the naïve and primed phases. Two phases of pluripotency, called naïve and primed, have previously been described.Formative pluripotency is an intermediate state of differentiation that we call "formative". It is proposed to exist as part of a developmental continuum between the naïve and primed phases. It consists of a gene regulatory network switch from the naïve state to the formative epiblast-like cells of EpiLCs. |
http://www.ncbi.nlm.nih.gov/pubmed/30668632 | Has the companion diagnostic HercepTest received FDA approval? | Yes, the HercepTest has received FDA approval. |
http://www.ncbi.nlm.nih.gov/pubmed/33156866 | Which R/Bioconductor package has been developed for visualizing differential amino acid group usage in proteomics? | DagLogo is an R/Bioconductor package for identifying and visualizing differential amino acid group usage in proteomics data. DagLogo allows various formats for input sets and provides comprehensive options to build optimal background models. It implements different reduced AA alphabets to group AAs of similar properties. Furthermore, dagLogo provides statistical and visual solutions for differential AA (or AA group) usage analysis of both large and small data sets. Case studies showed that dagLogo can better identify and visualize conserved protein sequence patterns from different types of inputs and can potentially reveal the biological patterns that could be missed by other logo generators.dagLogo is an R/Bioconductor package for identifying and visualizing differential amino acid group usage in data. dagLogo allows various formats for input sets and provides comprehensive options to build optimal background models.DagLogo is an R/Bioconductor package for identifying and visualizing differential amino acid group usage in proteomics data. |
http://www.ncbi.nlm.nih.gov/pubmed/32170867,http://www.ncbi.nlm.nih.gov/pubmed/32569380,http://www.ncbi.nlm.nih.gov/pubmed/33085860,http://www.ncbi.nlm.nih.gov/pubmed/20038231,http://www.ncbi.nlm.nih.gov/pubmed/33168588 | Dasatinib and Blinatumomab are used for treatment of which disease? | Dasatinib and Blinatumomab produces molecular responses in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. |
http://www.ncbi.nlm.nih.gov/pubmed/31883179,http://www.ncbi.nlm.nih.gov/pubmed/31911238,http://www.ncbi.nlm.nih.gov/pubmed/32004540,http://www.ncbi.nlm.nih.gov/pubmed/32001301,http://www.ncbi.nlm.nih.gov/pubmed/32058049 | Is phosphoenolpyruvate carboxykinase 1 (PCK1) the rate-limiting enzyme in gluconeogenesis? | Yes, Pck1 is a rate-limiting gluconeogenic enzyme, where its deficiency or mutation contributes to serious clinical situations as neonatal hypoglycemia and liver failure. |
http://www.ncbi.nlm.nih.gov/pubmed/21681130,http://www.ncbi.nlm.nih.gov/pubmed/32299690,http://www.ncbi.nlm.nih.gov/pubmed/32474897,http://www.ncbi.nlm.nih.gov/pubmed/28284457,http://www.ncbi.nlm.nih.gov/pubmed/24876682,http://www.ncbi.nlm.nih.gov/pubmed/30349795,http://www.ncbi.nlm.nih.gov/pubmed/28828917,http://www.ncbi.nlm.nih.gov/pubmed/32698624,http://www.ncbi.nlm.nih.gov/pubmed/18984333,http://www.ncbi.nlm.nih.gov/pubmed/27625547,http://www.ncbi.nlm.nih.gov/pubmed/26330768,http://www.ncbi.nlm.nih.gov/pubmed/33054988,http://www.ncbi.nlm.nih.gov/pubmed/19774420,http://www.ncbi.nlm.nih.gov/pubmed/23855039,http://www.ncbi.nlm.nih.gov/pubmed/29036022 | What conditions are diagnosed using the scratch collapse test? | Scouring collapse test is used for the diagnosis of cts, cubital tunnel syndrome and carpal tunnel syndrome.The scratch collapse test (SCT) is a clinical examination maneuver that has been reported as a reliable and reproducible test to diagnose carpal tunnel syndrome (CTS) cubital tunnel syndrome and other compressive upper limb neuropathies.Scales collapse test is used for the diagnosis of cts, cubital tunnel syndrome and carpal tunnel syndrome.Scratch collapse test is used for the diagnosis of cts, cubital tunnel syndrome and carpal tunnel syndrome.Evaluation of the Scratch Collapse Test for Carpal and Cubital Tunnel Syndrome-A Prospective, Blinded Study.Scrap collapse test is used for the diagnosis of cts, cubital tunnel syndrome and carpal tunnel syndrome. A diagnostic maneuver known as the "scratch-collapse test" (SCT), to aid in the diagnosis of compressive upper limb neuropathies such as carpal tunnel syndrome (CTS), |
http://www.ncbi.nlm.nih.gov/pubmed/23400715,http://www.ncbi.nlm.nih.gov/pubmed/15593221,http://www.ncbi.nlm.nih.gov/pubmed/18075793,http://www.ncbi.nlm.nih.gov/pubmed/27009916,http://www.ncbi.nlm.nih.gov/pubmed/19790071,http://www.ncbi.nlm.nih.gov/pubmed/30745462,http://www.ncbi.nlm.nih.gov/pubmed/31130331,http://www.ncbi.nlm.nih.gov/pubmed/25861459,http://www.ncbi.nlm.nih.gov/pubmed/31044165,http://www.ncbi.nlm.nih.gov/pubmed/28130918,http://www.ncbi.nlm.nih.gov/pubmed/32334613,http://www.ncbi.nlm.nih.gov/pubmed/17849124,http://www.ncbi.nlm.nih.gov/pubmed/20538795,http://www.ncbi.nlm.nih.gov/pubmed/24598455,http://www.ncbi.nlm.nih.gov/pubmed/31660791,http://www.ncbi.nlm.nih.gov/pubmed/24379124,http://www.ncbi.nlm.nih.gov/pubmed/19479852,http://www.ncbi.nlm.nih.gov/pubmed/15511676,http://www.ncbi.nlm.nih.gov/pubmed/23754736,http://www.ncbi.nlm.nih.gov/pubmed/29644082,http://www.ncbi.nlm.nih.gov/pubmed/23028528,http://www.ncbi.nlm.nih.gov/pubmed/24839407,http://www.ncbi.nlm.nih.gov/pubmed/12642603,http://www.ncbi.nlm.nih.gov/pubmed/24834763,http://www.ncbi.nlm.nih.gov/pubmed/31890206,http://www.ncbi.nlm.nih.gov/pubmed/23083033,http://www.ncbi.nlm.nih.gov/pubmed/30185417,http://www.ncbi.nlm.nih.gov/pubmed/27723281,http://www.ncbi.nlm.nih.gov/pubmed/27094810,http://www.ncbi.nlm.nih.gov/pubmed/21803750,http://www.ncbi.nlm.nih.gov/pubmed/19968664,http://www.ncbi.nlm.nih.gov/pubmed/22242767 | Which is the main gene signature in Systemic Lupus Erythematosus (SLE)? | Systemic Lupus Erythematosus (SLE) has a type I interferon (IFN) gene signature.SLE is characterized by a type-I interferon gene signature.Systemic Lupus Erythematosus (SLE) is a type I interferon (IFN) disease. The main gene signature is a 4-gene expression of 4 genes.SLE is characterized by dysregulation of both the innate and the adaptive immune systems. An increased expression of type I IFN-regulated genes, termed IFN signature, has been reported in patients with SLE.A role for interferon (IFN) in systemic lupus erythematosus (SLE) pathogenesis is inferred from the prominent IFN gene signature (IGS), but the major IFN species and its relationship to disease activity are unknown. |
http://www.ncbi.nlm.nih.gov/pubmed/31785606 | Has FTY720 been considered for the treatment of stroke? | Yes, FTY720 is a strong candidate for stroke treatment. |
http://www.ncbi.nlm.nih.gov/pubmed/30977807,http://www.ncbi.nlm.nih.gov/pubmed/30500173,http://www.ncbi.nlm.nih.gov/pubmed/28989334,http://www.ncbi.nlm.nih.gov/pubmed/32168452 | List R packages for lipidomics | R packages for lipidomics: lipidomics, masspix, lipidms, lipidr and lipid mini-on.R packages for lipidomics include: lipidr, masspix, lipidms, lipidr and lipid mini-on.Lipidomics, masspix, lipidms, lipidr and lipid mini-on are R packages for lipidomics.Lipid Mini-On, lipidr, LipidMS and massPix |
http://www.ncbi.nlm.nih.gov/pubmed/32674208,http://www.ncbi.nlm.nih.gov/pubmed/32674616,http://www.ncbi.nlm.nih.gov/pubmed/30741797,http://www.ncbi.nlm.nih.gov/pubmed/30937733,http://www.ncbi.nlm.nih.gov/pubmed/32469183,http://www.ncbi.nlm.nih.gov/pubmed/32911575,http://www.ncbi.nlm.nih.gov/pubmed/32273183,http://www.ncbi.nlm.nih.gov/pubmed/32912633,http://www.ncbi.nlm.nih.gov/pubmed/31461087,http://www.ncbi.nlm.nih.gov/pubmed/31594635 | Which disease can be treated with Relugolix. | Relugolix has a role in treatment of prostate cancer, uterine fibroids, endometriosis and uterine myomas. |
http://www.ncbi.nlm.nih.gov/pubmed/33084067,http://www.ncbi.nlm.nih.gov/pubmed/33246707 | What is the effect of Carbendazim on bees? | Carbendazim is an environmental risk factor that likely weakens bee colonies, partially due to reduced expression of major royal jelly proteins, which may be potential causes of colony collapse disorder. |
http://www.ncbi.nlm.nih.gov/pubmed/7991969,http://www.ncbi.nlm.nih.gov/pubmed/3058076,http://www.ncbi.nlm.nih.gov/pubmed/15836453,http://www.ncbi.nlm.nih.gov/pubmed/11900681,http://www.ncbi.nlm.nih.gov/pubmed/15143221,http://www.ncbi.nlm.nih.gov/pubmed/6065875,http://www.ncbi.nlm.nih.gov/pubmed/3653618,http://www.ncbi.nlm.nih.gov/pubmed/8419235,http://www.ncbi.nlm.nih.gov/pubmed/10409171,http://www.ncbi.nlm.nih.gov/pubmed/31951513,http://www.ncbi.nlm.nih.gov/pubmed/7549047,http://www.ncbi.nlm.nih.gov/pubmed/3049055,http://www.ncbi.nlm.nih.gov/pubmed/2666281,http://www.ncbi.nlm.nih.gov/pubmed/2052626,http://www.ncbi.nlm.nih.gov/pubmed/8026537,http://www.ncbi.nlm.nih.gov/pubmed/19799700 | What 3 organs are the sphincter of Oddi associated with? | Sphincter of Oddi is associated with the pancreatic duct, duodenum and gallbladder.The sphincter of Oddi is associated with the pancreatic duct, the duodenal crypts and gallbladder.Sphincter of Oddi (SO) is a dynamic structure located strategically at the confluence of the bile duct, the pancreatic duct and the duodenum.The sphincter of oddsi is associated with the pancreatic duct, the duodenal crypts and the gallbladder.The sphincter ofoddi is associated with the pancreatic duct, the duodenal crypts and gallbladder.The sphincter of Oddi is a dynamic structure located strategically at the confluence of the bile duct, the pancreatic duct and the duodenum. |
http://www.ncbi.nlm.nih.gov/pubmed/33150406 | List clinical phenotypes and molecular genetic features of patients with KMT2B-related disorders | Atypical patterns of dystonia evolution and a subgroup of patients presents with a non-dystonic neurodevelopmental phenotype. In addition to the previously reported systemic features there seem to be co-morbidities, including the risk of status dystonicus, intrauterine growth retardation, and endocrinopathies.KMT2B-related disorders result in significant improvement in motor function and disability at 6 months, 1 year, and again at 1 year after stimulation. The greatest improvements are seen for trunk and cervical dystonia, with less clinical impact on laryngeal or transternal dystonias. Patients with chromosomal deletions and protein truncating variants have a higher burden of systemic disease than those with missense variants. |
http://www.ncbi.nlm.nih.gov/pubmed/32297990,http://www.ncbi.nlm.nih.gov/pubmed/33142014,http://www.ncbi.nlm.nih.gov/pubmed/34521260,http://www.ncbi.nlm.nih.gov/pubmed/34813050,http://www.ncbi.nlm.nih.gov/pubmed/34407343,http://www.ncbi.nlm.nih.gov/pubmed/33369482,http://www.ncbi.nlm.nih.gov/pubmed/34788240 | What is the use of Atogepant? | Atogepant is used for preventive treatment of migraine. |
http://www.ncbi.nlm.nih.gov/pubmed/33710643,http://www.ncbi.nlm.nih.gov/pubmed/34876240,http://www.ncbi.nlm.nih.gov/pubmed/32355542,http://www.ncbi.nlm.nih.gov/pubmed/32908163 | Is SMOC2 expressed during wound healing? | Yes,
SMOC2 response to wounding. |
http://www.ncbi.nlm.nih.gov/pubmed/28900272,http://www.ncbi.nlm.nih.gov/pubmed/33787719,http://www.ncbi.nlm.nih.gov/pubmed/32125014,http://www.ncbi.nlm.nih.gov/pubmed/34884765,http://www.ncbi.nlm.nih.gov/pubmed/34149436 | What is a potential alternate uses(repositioning) for Primaquine | Primaquine Diphosphate, a Known Antimalarial Drug, Blocks Vascular Leakage Acting Through Junction Stabilization. PD could be used as a novel drug for vascular leakage by maintaining endothelial integrityPrimaquine could be used as a novel drug for vascular leakage by maintaining endothelial integrity and forPrimaquine Diphosphate, a known Antimalarial Drug, blocks Vascular Leakage through Junction Stabilization. This is a potential alternate uses. |
http://www.ncbi.nlm.nih.gov/pubmed/34881402 | Does daily atemoya juice intake change the pharmacokinetics of CYP1A2 substrates? | No, atemoya juice does not change the pharmacokinetics of CYP1A2 substrates. |
http://www.ncbi.nlm.nih.gov/pubmed/33782605 | What is caused by gain-of-function variants in SYK? | Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice.SYK gain-of-function variants cause immune dysregulation and systemic inflammation in humans and mice. |
http://www.ncbi.nlm.nih.gov/pubmed/32492704,http://www.ncbi.nlm.nih.gov/pubmed/27799824,http://www.ncbi.nlm.nih.gov/pubmed/34482355,http://www.ncbi.nlm.nih.gov/pubmed/34379922,http://www.ncbi.nlm.nih.gov/pubmed/34029457,http://www.ncbi.nlm.nih.gov/pubmed/32462541,http://www.ncbi.nlm.nih.gov/pubmed/33347943,http://www.ncbi.nlm.nih.gov/pubmed/30811880,http://www.ncbi.nlm.nih.gov/pubmed/26633643,http://www.ncbi.nlm.nih.gov/pubmed/34871188,http://www.ncbi.nlm.nih.gov/pubmed/29633869,http://www.ncbi.nlm.nih.gov/pubmed/33740057,http://www.ncbi.nlm.nih.gov/pubmed/30012774,http://www.ncbi.nlm.nih.gov/pubmed/31644481,http://www.ncbi.nlm.nih.gov/pubmed/33112699,http://www.ncbi.nlm.nih.gov/pubmed/31447590,http://www.ncbi.nlm.nih.gov/pubmed/33957367,http://www.ncbi.nlm.nih.gov/pubmed/26049948,http://www.ncbi.nlm.nih.gov/pubmed/29746267,http://www.ncbi.nlm.nih.gov/pubmed/26049951,http://www.ncbi.nlm.nih.gov/pubmed/30445896 | Is Cabotegravir effective for HIV prevention? | Yes, Cabotegravir is effective for HIV prevention. |
http://www.ncbi.nlm.nih.gov/pubmed/34599615,http://www.ncbi.nlm.nih.gov/pubmed/34506649,http://www.ncbi.nlm.nih.gov/pubmed/34136961,http://www.ncbi.nlm.nih.gov/pubmed/34564289,http://www.ncbi.nlm.nih.gov/pubmed/31822819,http://www.ncbi.nlm.nih.gov/pubmed/34517785 | What is the function of the protein SERT? | SERT is a Serotonin transporter. |
http://www.ncbi.nlm.nih.gov/pubmed/33213893,http://www.ncbi.nlm.nih.gov/pubmed/34459951,http://www.ncbi.nlm.nih.gov/pubmed/28620243,http://www.ncbi.nlm.nih.gov/pubmed/26845351,http://www.ncbi.nlm.nih.gov/pubmed/26908447,http://www.ncbi.nlm.nih.gov/pubmed/24030712 | Are G-quadruplexes(G4) possible drug targets for glioblastoma? | The 2H2-6M(4)-oxazole telomestatin derivative (6OTD) targets Glioma stem cells through G4 stabilization and promotion of DNA damage responses. Therefore, G4s are promising therapeutic targets for glioblastoma.G-quadruplex DNA structures (G4 DNA) are a promising therapeutic target for glioblastoma because of their ability to stabilize DNA damage and promote DNA damage response in response to 6-oxazole 6-methyl-CoA reductase inhibitors (6OTD). |
http://www.ncbi.nlm.nih.gov/pubmed/32589708 | Is RUNX1T1 associate with obesity? | Yes, the rs34269950 SNP of the RUNX1T1 gene was significantly associated with obesity risk and metabolic abnormalities. Specifically, compared to AA genotype, rs34269950 del/del genotype was associated with a 1.47 [95% confidence interval (CI): 1.01-2.14, P = 0.042] fold higher rate of obesity risk. |
http://www.ncbi.nlm.nih.gov/pubmed/28145888 | Is Adamts18 deficiency associated with cancer? | Yes. ADAMTS18 is a novel tumor suppressor and is critical to the pathology of human colorectal cancer. Adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated Wnt/β-catenin and p38MAPK/ERK1/2 signaling and promotes colon cancer in this mouse model. |
http://www.ncbi.nlm.nih.gov/pubmed/30349847,http://www.ncbi.nlm.nih.gov/pubmed/29087095,http://www.ncbi.nlm.nih.gov/pubmed/24399399,http://www.ncbi.nlm.nih.gov/pubmed/30672496,http://www.ncbi.nlm.nih.gov/pubmed/28710682,http://www.ncbi.nlm.nih.gov/pubmed/25116781,http://www.ncbi.nlm.nih.gov/pubmed/17211660 | What causes Ocular Thelaziasis? | Ocular Thelaziasis is caused by Thelazia callipaeda. |
http://www.ncbi.nlm.nih.gov/pubmed/34819671,http://www.ncbi.nlm.nih.gov/pubmed/34819670,http://www.ncbi.nlm.nih.gov/pubmed/32729075,http://www.ncbi.nlm.nih.gov/pubmed/34528388,http://www.ncbi.nlm.nih.gov/pubmed/32729074 | What is the role of cytidine deaminase in healthy cells? | Activation-induced cytidine deaminase (AID) catalyses the deamination of deoxycytidines to deoxyuracils within immunoglobulin genes to induce somatic hypermutation and class-switch recombination. |
http://www.ncbi.nlm.nih.gov/pubmed/32266540,http://www.ncbi.nlm.nih.gov/pubmed/31639609,http://www.ncbi.nlm.nih.gov/pubmed/15316156,http://www.ncbi.nlm.nih.gov/pubmed/9629399,http://www.ncbi.nlm.nih.gov/pubmed/34159894,http://www.ncbi.nlm.nih.gov/pubmed/34535635,http://www.ncbi.nlm.nih.gov/pubmed/9048937,http://www.ncbi.nlm.nih.gov/pubmed/33219521,http://www.ncbi.nlm.nih.gov/pubmed/26123252,http://www.ncbi.nlm.nih.gov/pubmed/34565721,http://www.ncbi.nlm.nih.gov/pubmed/32346735 | Summarize the cause of autosomal dominant Spinocerebellar Ataxia type 3. | Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a progressive autosomal dominant neurodegenerative disease caused by abnormal CAG repeats in the exon 10 of ATXN3.Spinocerebellar ataxia type 3/Machado-Joseph disease (SCA3/MJD) is a dominant neurodegenerative disease caused by the expansion of a CAG repeat tract in ATXN3. |
http://www.ncbi.nlm.nih.gov/pubmed/34513292 | Through which pathway does the FTO-guided demethylation of GADD46 drive myogenesis? | FTO-mediated demethylation of GADD45B promotes myogenesis through the activation of p38 MAPK pathway. |
http://www.ncbi.nlm.nih.gov/pubmed/33909992 | What are the key characteristics of the syndrome caused by ANKRD17 loss-of-function variants? | Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphia.Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism.Heterozygous ANKRD17 loss-of-function variants cause a syndrome with intellectual disability, speech delay, and dysmorphism, as well as growth failure, feeding difficulties, non-specific MRI abnormalities, epilepsy, and/or abnormal EEG, and predisposition to recurrent infections. |
http://www.ncbi.nlm.nih.gov/pubmed/33438008,http://www.ncbi.nlm.nih.gov/pubmed/34423657,http://www.ncbi.nlm.nih.gov/pubmed/34587385,http://www.ncbi.nlm.nih.gov/pubmed/27144850,http://www.ncbi.nlm.nih.gov/pubmed/29608575,http://www.ncbi.nlm.nih.gov/pubmed/29766731,http://www.ncbi.nlm.nih.gov/pubmed/27049060 | Is Ozanimod effective for Ulcerative Colitis? | Yes, Ozanimod is effective for Ulcerative Colitis. |
http://www.ncbi.nlm.nih.gov/pubmed/34766984,http://www.ncbi.nlm.nih.gov/pubmed/34687906,http://www.ncbi.nlm.nih.gov/pubmed/34548087,http://www.ncbi.nlm.nih.gov/pubmed/34489534 | What is the function of the protein PIEZO1? | Piezo1 is a key element of the mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations. |
http://www.ncbi.nlm.nih.gov/pubmed/31122188,http://www.ncbi.nlm.nih.gov/pubmed/28240610,http://www.ncbi.nlm.nih.gov/pubmed/33363597,http://www.ncbi.nlm.nih.gov/pubmed/33856626,http://www.ncbi.nlm.nih.gov/pubmed/29616494,http://www.ncbi.nlm.nih.gov/pubmed/32145209,http://www.ncbi.nlm.nih.gov/pubmed/29722276,http://www.ncbi.nlm.nih.gov/pubmed/33542885,http://www.ncbi.nlm.nih.gov/pubmed/29691490,http://www.ncbi.nlm.nih.gov/pubmed/34246226,http://www.ncbi.nlm.nih.gov/pubmed/33765912,http://www.ncbi.nlm.nih.gov/pubmed/26879279,http://www.ncbi.nlm.nih.gov/pubmed/26432182,http://www.ncbi.nlm.nih.gov/pubmed/34742252,http://www.ncbi.nlm.nih.gov/pubmed/30413151,http://www.ncbi.nlm.nih.gov/pubmed/31985655,http://www.ncbi.nlm.nih.gov/pubmed/33023473,http://www.ncbi.nlm.nih.gov/pubmed/30106172,http://www.ncbi.nlm.nih.gov/pubmed/31020659,http://www.ncbi.nlm.nih.gov/pubmed/33892641,http://www.ncbi.nlm.nih.gov/pubmed/31050694,http://www.ncbi.nlm.nih.gov/pubmed/29171818,http://www.ncbi.nlm.nih.gov/pubmed/30360965,http://www.ncbi.nlm.nih.gov/pubmed/34115380,http://www.ncbi.nlm.nih.gov/pubmed/34363708,http://www.ncbi.nlm.nih.gov/pubmed/30886915,http://www.ncbi.nlm.nih.gov/pubmed/34544359 | Please list 3 biologic(monoclonal antibody) drugs used to treat migraine headaches. | Large molecule biologic antibody (mAb) approaches that are given subcutaneously to neutralize circulating CGRP peptide (fremanezumab, galcanezumab) or block CGRP receptors (erenumab) have shown consistent efficacy and tolerability in multicenter migraine prevention trials and are now approved for clinical use.Large molecule biologic antibody (mAb) approaches that are given subcutaneously to neutralize circulating CGRP peptide (fremanezumab, galcanezumab) or block CGRP receptors (erenumab) have shown consistent efficacy and tolerability in multicenter migraine prevention trials and are now approved for clinical use. |
http://www.ncbi.nlm.nih.gov/pubmed/32589708 | What is the most common N6-methyladenosine (m6A) methylation modification site of RUNX1T1? | The RRACH motif is the most common N6-methyladenosine (m6A) methylation modification site of RUNX1T1. |
http://www.ncbi.nlm.nih.gov/pubmed/34757206 | Describe GREEKC | The COST Action Gene Regulation Ensemble Effort for the Knowledge Commons (GREEKC, CA15205, www.greekc.org) organized nine workshops in a four-year period, starting September 2016. The workshops brought together experts from all over the world working on various steps in the knowledge management process that focuses on understanding gene regulatory mechanisms.As computational modeling becomes more essential to analyze and understand biological regulatory mechanisms, governance of the many databases and knowledge bases that support this domain is crucial to guarantee reliability and interoperability of resources. To address this, the COST Action Gene Regulation Ensemble Effort for the Knowledge Commons (GREEKC, CA15205, www.greekc.org) organized nine workshops in a four-year period, starting September 2016. The workshops brought together a wide range of experts from all over the world working on various steps in the knowledge management process that focuses on understanding gene regulatory mechanisms. The discussions between ontologists, curators, text miners, biologists, bioinformaticians, philosophers and computational scientists spawned a host of activities aimed to standardize and update existing knowledge management workflows and involve end-users in the process of designing the Gene Regulation Knowledge Commons (GRKC). |
http://www.ncbi.nlm.nih.gov/pubmed/34542221,http://www.ncbi.nlm.nih.gov/pubmed/32291277,http://www.ncbi.nlm.nih.gov/pubmed/32519795,http://www.ncbi.nlm.nih.gov/pubmed/33236115,http://www.ncbi.nlm.nih.gov/pubmed/34431633,http://www.ncbi.nlm.nih.gov/pubmed/34626443,http://www.ncbi.nlm.nih.gov/pubmed/34518444,http://www.ncbi.nlm.nih.gov/pubmed/34003802,http://www.ncbi.nlm.nih.gov/pubmed/33778934,http://www.ncbi.nlm.nih.gov/pubmed/34819089,http://www.ncbi.nlm.nih.gov/pubmed/34608929,http://www.ncbi.nlm.nih.gov/pubmed/34370970,http://www.ncbi.nlm.nih.gov/pubmed/34170647,http://www.ncbi.nlm.nih.gov/pubmed/32730231,http://www.ncbi.nlm.nih.gov/pubmed/33325008,http://www.ncbi.nlm.nih.gov/pubmed/33030356,http://www.ncbi.nlm.nih.gov/pubmed/34681215 | Which receptors are targeted by Tirzepatide? | Tirzepatide is dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that demonstrated substantially greater glucose control and weight loss (WL) compared with selective GLP-1RA dulaglutide. |
http://www.ncbi.nlm.nih.gov/pubmed/19441788,http://www.ncbi.nlm.nih.gov/pubmed/22223758,http://www.ncbi.nlm.nih.gov/pubmed/23576690,http://www.ncbi.nlm.nih.gov/pubmed/24957772,http://www.ncbi.nlm.nih.gov/pubmed/33303693,http://www.ncbi.nlm.nih.gov/pubmed/20412957 | Is esophageal adenocarcinoma associated with aberrant glycosylation? | Yes,
Altered glycoprotein expression has been demonstrated in tissue from patients with Barrett's esophagus and esophageal cancer but the mechanisms regarding such changes are unknown. |
http://www.ncbi.nlm.nih.gov/pubmed/14634002,http://www.ncbi.nlm.nih.gov/pubmed/26492771,http://www.ncbi.nlm.nih.gov/pubmed/11295228,http://www.ncbi.nlm.nih.gov/pubmed/19843217,http://www.ncbi.nlm.nih.gov/pubmed/28731469,http://www.ncbi.nlm.nih.gov/pubmed/9337202,http://www.ncbi.nlm.nih.gov/pubmed/18511909,http://www.ncbi.nlm.nih.gov/pubmed/22297519,http://www.ncbi.nlm.nih.gov/pubmed/12354605,http://www.ncbi.nlm.nih.gov/pubmed/25986150,http://www.ncbi.nlm.nih.gov/pubmed/30484157,http://www.ncbi.nlm.nih.gov/pubmed/29696145,http://www.ncbi.nlm.nih.gov/pubmed/28961247,http://www.ncbi.nlm.nih.gov/pubmed/30484150,http://www.ncbi.nlm.nih.gov/pubmed/28963798,http://www.ncbi.nlm.nih.gov/pubmed/21702926,http://www.ncbi.nlm.nih.gov/pubmed/15362106,http://www.ncbi.nlm.nih.gov/pubmed/21265753,http://www.ncbi.nlm.nih.gov/pubmed/10380224,http://www.ncbi.nlm.nih.gov/pubmed/15677470,http://www.ncbi.nlm.nih.gov/pubmed/17489689 | What is the function of a chaperonin? | Molecular chaperones promote the correct folding of proteins in aggregation-prone cellular environments by stabilizing nascent polypeptide chains and providing appropriate folding conditions. They are involved in the development of pathological processes, including--atherosclerosis and coronary heart disease.Chaperonins assist in the acquisition of native protein structure in the cell by providing a shielded environment for a folding polypeptide chain, generated by the interior surface of their cylindrical structure.Molecular chaperones promote the correct folding of proteins in aggregation-prone cellular environments by stabilizing nascent polypeptide chains and providing appropriate folding conditions. |
http://www.ncbi.nlm.nih.gov/pubmed/34484859 | Can FTO promote pancreatic cancer development? | No, the m6A demethylase FTO suppresses pancreatic cancer tumorigenesis. |
http://www.ncbi.nlm.nih.gov/pubmed/33252155 | Which disorder is caused by biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1)? | Biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB).Biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB)Biallelic mutations in G-Protein coupled receptor kinase 1 (GRK1) cause Oguchi disease, a rare subtype of congenital stationary night blindness (CSNB), which is caused by a protein-coupled receptor-protein interaction. |
http://www.ncbi.nlm.nih.gov/pubmed/32725406,http://www.ncbi.nlm.nih.gov/pubmed/34551229,http://www.ncbi.nlm.nih.gov/pubmed/34885078,http://www.ncbi.nlm.nih.gov/pubmed/33839690,http://www.ncbi.nlm.nih.gov/pubmed/32273508,http://www.ncbi.nlm.nih.gov/pubmed/32816891 | Which disease is treated with Tebentafusp? | Tebentafusp is used for treatment of Metastatic Uveal Melanoma. |
http://www.ncbi.nlm.nih.gov/pubmed/34431892,http://www.ncbi.nlm.nih.gov/pubmed/32081946,http://www.ncbi.nlm.nih.gov/pubmed/32227027,http://www.ncbi.nlm.nih.gov/pubmed/33964291,http://www.ncbi.nlm.nih.gov/pubmed/34384745,http://www.ncbi.nlm.nih.gov/pubmed/31839581 | Is Lysozyme abundant in human tears? | Yes,
lysozyme is the most prevalent protein in tear fluid. |
http://www.ncbi.nlm.nih.gov/pubmed/27512149,http://www.ncbi.nlm.nih.gov/pubmed/32010240,http://www.ncbi.nlm.nih.gov/pubmed/15585845,http://www.ncbi.nlm.nih.gov/pubmed/12890516,http://www.ncbi.nlm.nih.gov/pubmed/11027662,http://www.ncbi.nlm.nih.gov/pubmed/11708803,http://www.ncbi.nlm.nih.gov/pubmed/17016626,http://www.ncbi.nlm.nih.gov/pubmed/18948835,http://www.ncbi.nlm.nih.gov/pubmed/10894543,http://www.ncbi.nlm.nih.gov/pubmed/32013887,http://www.ncbi.nlm.nih.gov/pubmed/31492042,http://www.ncbi.nlm.nih.gov/pubmed/28291683,http://www.ncbi.nlm.nih.gov/pubmed/32462086,http://www.ncbi.nlm.nih.gov/pubmed/11853869,http://www.ncbi.nlm.nih.gov/pubmed/25605682,http://www.ncbi.nlm.nih.gov/pubmed/19324999,http://www.ncbi.nlm.nih.gov/pubmed/32888314,http://www.ncbi.nlm.nih.gov/pubmed/31899262 | What is Neuromedin U (NmU) | Neuromedin U (NmU) is a highly conserved neuropeptide and has multiple physiological and pathophysiological roles detected, ranging from smooth muscle contraction, feeding, energy balance to tumorigenesis, stress responses, and inflammation.Neuromedin U (NmU) is a bioactive neuropeptide that is highly distributed in the central nervous system and the gastrointestinal tract. It has a number of physiological and pathophysiological roles, ranging from feeding behavior, energy metabolism, stress responses, circadian rhythmicity and inflammation. |
http://www.ncbi.nlm.nih.gov/pubmed/31785606 | Is FTY720 FDA approved? | Yes, FTY720 was approved by the US Food and Drug Administration (FDA) in 2010. |
http://www.ncbi.nlm.nih.gov/pubmed/31116370 | Describe SPar-K | SPar-K is a method to search for archetypical chromatin architectures by partitioning a set of genomic regions characterized by chromatin signal profiles around ChIP-seq peaks and other kinds of functional sites. This method efficiently deals with problems of data heterogeneity, limited misalignment of anchor points and unknown orientation of asymmetric patterns.SPar-K (Signal Partitioning with K-means) is a method to search for archetypical chromatin architectures by partitioning a set of genomic regions characterized by chromatin signal profiles around ChIP-seq peaks and other kinds of functional sites. This method efficiently deals with problems of data heterogeneity, limited misalignment of anchor points and unknown orientation of asymmetric patterns.SPar-K (Signal Partitioning with K-means) is a method to search for archetypical chromatin architectures by partitioning a set of genomic regions characterized by chromatin signal profiles around ChIP-seq peaks and other functional sites. |
http://www.ncbi.nlm.nih.gov/pubmed/34585215,http://www.ncbi.nlm.nih.gov/pubmed/34489680,http://www.ncbi.nlm.nih.gov/pubmed/34162295,http://www.ncbi.nlm.nih.gov/pubmed/34769222,http://www.ncbi.nlm.nih.gov/pubmed/33720637,http://www.ncbi.nlm.nih.gov/pubmed/34880449,http://www.ncbi.nlm.nih.gov/pubmed/34536669,http://www.ncbi.nlm.nih.gov/pubmed/34198582 | What is the mechanism of action of donanemab? | Donanemab is a new monoclonal antibody that uniquely targets Aβ(p3-42), a pyroglutamate form of Amyloid-β (Aβ) exclusively found in plaques. |
http://www.ncbi.nlm.nih.gov/pubmed/33321564,http://www.ncbi.nlm.nih.gov/pubmed/34593462,http://www.ncbi.nlm.nih.gov/pubmed/34163223,http://www.ncbi.nlm.nih.gov/pubmed/32577996 | Is cytokeratin a tumor marker? | Yes,
cytokeratin 19 fragment antigen 21-1 (CYFRA21-1) is a tumor marker. |
http://www.ncbi.nlm.nih.gov/pubmed/33568427,http://www.ncbi.nlm.nih.gov/pubmed/29730267,http://www.ncbi.nlm.nih.gov/pubmed/34060821,http://www.ncbi.nlm.nih.gov/pubmed/34006822,http://www.ncbi.nlm.nih.gov/pubmed/32708142,http://www.ncbi.nlm.nih.gov/pubmed/28341752,http://www.ncbi.nlm.nih.gov/pubmed/34276698,http://www.ncbi.nlm.nih.gov/pubmed/32445205,http://www.ncbi.nlm.nih.gov/pubmed/25620672,http://www.ncbi.nlm.nih.gov/pubmed/34469109,http://www.ncbi.nlm.nih.gov/pubmed/29436395,http://www.ncbi.nlm.nih.gov/pubmed/34515617,http://www.ncbi.nlm.nih.gov/pubmed/29691294,http://www.ncbi.nlm.nih.gov/pubmed/33050070,http://www.ncbi.nlm.nih.gov/pubmed/31704343,http://www.ncbi.nlm.nih.gov/pubmed/33881837,http://www.ncbi.nlm.nih.gov/pubmed/34695762 | What are TAMs in cancer therapy? | TAMs are Tumor Associated Macrophages and are important in Cancer therapy. |
http://www.ncbi.nlm.nih.gov/pubmed/25881961,http://www.ncbi.nlm.nih.gov/pubmed/25412662 | What is the relationship between RUNX1T1 and FTO? | FTO controls exonic splicing of adipogenic regulatory factor RUNX1T1 by regulating m6A levels around splice sites and thereby modulates differentiation. The effect of FTO on adipogenesis appears to be mediated via enhanced expression of the pro-adipogenic short isoform of RUNX1T1. |
http://www.ncbi.nlm.nih.gov/pubmed/31250907 | Which java utility has been developed for class hidden markov models? | JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols, and is used for biological sequence analysis and class hidden markov models in Java EE 8 and Java EE 9.JUCHMME is an open-source software package designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols.JUCHMME is an open-source software package in Java designed to fit arbitrary custom Hidden Markov Models (HMMs) with a discrete alphabet of symbols. |
http://www.ncbi.nlm.nih.gov/pubmed/34537363,http://www.ncbi.nlm.nih.gov/pubmed/34555986,http://www.ncbi.nlm.nih.gov/pubmed/34006961,http://www.ncbi.nlm.nih.gov/pubmed/34514598,http://www.ncbi.nlm.nih.gov/pubmed/33972256,http://www.ncbi.nlm.nih.gov/pubmed/34374951,http://www.ncbi.nlm.nih.gov/pubmed/34504497,http://www.ncbi.nlm.nih.gov/pubmed/34511939,http://www.ncbi.nlm.nih.gov/pubmed/34433754 | What is the mechanism of action of Etesevimab? | Etesevimab is a neutralizing antibody indicated for treatment of coronavirus disease 2019 (COVID-19) in patients with early mild or moderate disease. |
http://www.ncbi.nlm.nih.gov/pubmed/34496019,http://www.ncbi.nlm.nih.gov/pubmed/34537014,http://www.ncbi.nlm.nih.gov/pubmed/32730594,http://www.ncbi.nlm.nih.gov/pubmed/34567510,http://www.ncbi.nlm.nih.gov/pubmed/34543009,http://www.ncbi.nlm.nih.gov/pubmed/32397857,http://www.ncbi.nlm.nih.gov/pubmed/32687661,http://www.ncbi.nlm.nih.gov/pubmed/34548332 | List known pseudokinases. | TRIB1
TRIB2
TRIB3
MLKL
ULK4
HER3
CASK |
http://www.ncbi.nlm.nih.gov/pubmed/11979138,http://www.ncbi.nlm.nih.gov/pubmed/8674142,http://www.ncbi.nlm.nih.gov/pubmed/2342879,http://www.ncbi.nlm.nih.gov/pubmed/28847272,http://www.ncbi.nlm.nih.gov/pubmed/3500086,http://www.ncbi.nlm.nih.gov/pubmed/31970486,http://www.ncbi.nlm.nih.gov/pubmed/31856298,http://www.ncbi.nlm.nih.gov/pubmed/848258,http://www.ncbi.nlm.nih.gov/pubmed/19874224,http://www.ncbi.nlm.nih.gov/pubmed/3029559,http://www.ncbi.nlm.nih.gov/pubmed/21439318,http://www.ncbi.nlm.nih.gov/pubmed/29395860,http://www.ncbi.nlm.nih.gov/pubmed/12206832,http://www.ncbi.nlm.nih.gov/pubmed/1905075,http://www.ncbi.nlm.nih.gov/pubmed/1548786,http://www.ncbi.nlm.nih.gov/pubmed/30298433,http://www.ncbi.nlm.nih.gov/pubmed/31734952,http://www.ncbi.nlm.nih.gov/pubmed/23135279,http://www.ncbi.nlm.nih.gov/pubmed/33236653,http://www.ncbi.nlm.nih.gov/pubmed/30021891,http://www.ncbi.nlm.nih.gov/pubmed/6743144,http://www.ncbi.nlm.nih.gov/pubmed/21461871 | Where is the body would the Peyer's patches be found | Peyer's patches (PPs) play a major role in intestinal mucosal immunity and are located in the gut. |
http://www.ncbi.nlm.nih.gov/pubmed/31721311 | Is tofacitinib a JAK inhibitor? | Yes, tofacitinib is a small JAK inhibitor. |
http://www.ncbi.nlm.nih.gov/pubmed/31802016 | Describe the GenomeAsia 100K Project | The GenomeAsia 100K Project (GenomeAsia100K Project) aims to identify and catalogue genetic variation, population structure, disease associations and founder effects in populations across Asia and worldwide. It includes a whole-genome sequencing reference dataset from 1,739 individuals of 219 population groups and 64 countries across Asia, as well as a population-wide association dataset.The underrepresentation of non-Europeans in human genetic studies so far has limited the diversity of individuals in genomic datasets and led to reduced medical relevance for a large proportion of the world's population. Population-specific reference genome datasets as well as genome-wide association studies in diverse populations are needed to address this issue. The pilot phase of the GenomeAsia 100K Project includes a whole-genome sequencing reference dataset from 1,739 individuals of 219 population groups and 64 countries across Asia. |
http://www.ncbi.nlm.nih.gov/pubmed/33098622,http://www.ncbi.nlm.nih.gov/pubmed/33626251,http://www.ncbi.nlm.nih.gov/pubmed/34888619,http://www.ncbi.nlm.nih.gov/pubmed/34745484,http://www.ncbi.nlm.nih.gov/pubmed/33231373,http://www.ncbi.nlm.nih.gov/pubmed/33044711,http://www.ncbi.nlm.nih.gov/pubmed/34183144,http://www.ncbi.nlm.nih.gov/pubmed/33919699,http://www.ncbi.nlm.nih.gov/pubmed/34287987,http://www.ncbi.nlm.nih.gov/pubmed/34141064,http://www.ncbi.nlm.nih.gov/pubmed/30302786,http://www.ncbi.nlm.nih.gov/pubmed/34368854,http://www.ncbi.nlm.nih.gov/pubmed/34347881,http://www.ncbi.nlm.nih.gov/pubmed/33130193,http://www.ncbi.nlm.nih.gov/pubmed/34283224,http://www.ncbi.nlm.nih.gov/pubmed/30044619,http://www.ncbi.nlm.nih.gov/pubmed/33458725,http://www.ncbi.nlm.nih.gov/pubmed/33283185 | Which disease is treated with Risdiplam? | Risdiplam is approved for spinal muscular atrophy. |
http://www.ncbi.nlm.nih.gov/pubmed/31812495,http://www.ncbi.nlm.nih.gov/pubmed/32003970,http://www.ncbi.nlm.nih.gov/pubmed/31935590,http://www.ncbi.nlm.nih.gov/pubmed/29189096 | What is protein palmitoylation? | Protein S-palmitoylation, the covalent lipid modification of the side chain of Cys residues with the 16‑carbon fatty acid palmitate, is the most common acylation, and it enhances the membrane stability of ion channels. This post-translational modification (PTM) determines a functional mechanism of ion channel life cycle from maturation and membrane trafficking to localization. |
http://www.ncbi.nlm.nih.gov/pubmed/15302523,http://www.ncbi.nlm.nih.gov/pubmed/23172095,http://www.ncbi.nlm.nih.gov/pubmed/1501489,http://www.ncbi.nlm.nih.gov/pubmed/2179633 | Αre plants from the genus Strychnos the original source of curare? | Species of plants from the genus Strychnos are the source of curare. |
http://www.ncbi.nlm.nih.gov/pubmed/30550780 | When was galcanezumab approved by FDA? | Galcanezumab was approved by the FDA in September 2018. |
http://www.ncbi.nlm.nih.gov/pubmed/33245860 | Are variants in FHF2 (also known as FGF13) associated with encephalopathy? | Yes. FHF2 (also known as FGF13) variants are a cause of infantile-onset developmental and epileptic encephalopathy. |
http://www.ncbi.nlm.nih.gov/pubmed/32640130,http://www.ncbi.nlm.nih.gov/pubmed/34704267 | Tofersen has been developed for treatment of which disease? | Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis is being studied for the treatment of amyotrophic lateral sclerosis due to SOD1 mutations. |
http://www.ncbi.nlm.nih.gov/pubmed/32048961,http://www.ncbi.nlm.nih.gov/pubmed/31802224,http://www.ncbi.nlm.nih.gov/pubmed/32443748,http://www.ncbi.nlm.nih.gov/pubmed/30617948,http://www.ncbi.nlm.nih.gov/pubmed/31904838 | What is the cause of lactose intolerance? | Lactose intolerance is a common condition caused by lactase deficiency and may result in symptoms of lactose malabsorption (bloating, flatulence, abdominal discomfort, and change in bowel habits).
Four clinical subtypes of lactose intolerance may be distinguished, namely lactase deficiency in premature infants, congenital lactase deficiency, adult-type hypolactasia and secondary lactase intolerance. |
http://www.ncbi.nlm.nih.gov/pubmed/30546611,http://www.ncbi.nlm.nih.gov/pubmed/33031544,http://www.ncbi.nlm.nih.gov/pubmed/32243020,http://www.ncbi.nlm.nih.gov/pubmed/25187742,http://www.ncbi.nlm.nih.gov/pubmed/17666930,http://www.ncbi.nlm.nih.gov/pubmed/11944589,http://www.ncbi.nlm.nih.gov/pubmed/33329156,http://www.ncbi.nlm.nih.gov/pubmed/31153990,http://www.ncbi.nlm.nih.gov/pubmed/2692969,http://www.ncbi.nlm.nih.gov/pubmed/20110024,http://www.ncbi.nlm.nih.gov/pubmed/33169539,http://www.ncbi.nlm.nih.gov/pubmed/33236683,http://www.ncbi.nlm.nih.gov/pubmed/25538342 | What is Etizolam? | Etizolam is a benzodiazepine analogue that is approved for use in Japan, Italy and India as an anxiolytic drug with a pharmacologic profile similar to that of the classic benzodiazepines. Neurochemical research suggests that etizolam may have selectivity for the subpopulation of Y-aminobutyric acid type A receptors associated with anxiety (ie, alpha1, beta2, gamma2).Etizolam is a thienodiazepine derivative, with high affinity for the benzodiazepine site of GABAA receptors. |
http://www.ncbi.nlm.nih.gov/pubmed/22197578 | Is AZD9668 a VEGF mRNA drug? | AZD9668 is a reversible and selective inhibitor of neutrophil elastase. |
http://www.ncbi.nlm.nih.gov/pubmed/33186545 | What is caused by de novo VPS4A mutations? | De novo VPS4A mutations cause multisystem disease with abnormal neurodevelopment. VPS4A normal function is required for multiple human developmental and cellular processes.De-novo VPS4A mutations cause multisystem disease with abnormal neurodevelopment, including dyskinesias, dyslipidemia, and dysplastic skin and cartilaginous neoplasia, as well as an inability to control intracranial temperature. |
http://www.ncbi.nlm.nih.gov/pubmed/34147650,http://www.ncbi.nlm.nih.gov/pubmed/31474439,http://www.ncbi.nlm.nih.gov/pubmed/33675755,http://www.ncbi.nlm.nih.gov/pubmed/34482398,http://www.ncbi.nlm.nih.gov/pubmed/33711380,http://www.ncbi.nlm.nih.gov/pubmed/33464651,http://www.ncbi.nlm.nih.gov/pubmed/34342834,http://www.ncbi.nlm.nih.gov/pubmed/33730455,http://www.ncbi.nlm.nih.gov/pubmed/34445916 | What is the use of pegcetacoplan? | Pegcetacoplan is promising for paroxysmal nocturnal haemoglobinuria and Geographic Atrophy. |
http://www.ncbi.nlm.nih.gov/pubmed/31769974,http://www.ncbi.nlm.nih.gov/pubmed/29178580,http://www.ncbi.nlm.nih.gov/pubmed/29282902,http://www.ncbi.nlm.nih.gov/pubmed/33997889,http://www.ncbi.nlm.nih.gov/pubmed/34493791 | What is the activity of a Oligosaccharyltransferases ? | oligosaccharyltransferases (OSTs), which catalyze the attachment of glycans to specific amino acid residues in target proteins |
http://www.ncbi.nlm.nih.gov/pubmed/10973238,http://www.ncbi.nlm.nih.gov/pubmed/22090721,http://www.ncbi.nlm.nih.gov/pubmed/15266619,http://www.ncbi.nlm.nih.gov/pubmed/10802661 | On what chromosome would the MKKS gene for McKusick-Kaufman(AKA Kaufman-McKusick) syndrome be found? | The MKKS gene is mapped to chromosome 20 |
http://www.ncbi.nlm.nih.gov/pubmed/28696420 | Which maternal CYP2D6 related phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding? | Mothers with a CYP2D6 ultrarapid metabolizer phenotype may expose their infants to risk of adverse events when taking codeine while breastfeeding, by producing more of the active metabolite, morphine. |
http://www.ncbi.nlm.nih.gov/pubmed/34139436 | Describe the web application VICTOR | VICTOR is a free, dependency-free visual analytics web application that allows the visual comparison of the results of various clustering algorithms. It can handle multiple cluster set results simultaneously and compare them using ten different metrics. Clustering results can be filtered and compared with the use of data tables or interactive heatmaps, bar plots, correlation networks, sankey and circos plots.VICTOR is a visual analytics web application which allows the visual comparison of the results of various clustering algorithms.VICTOR is the first fully interactive and dependency-free visual analytics web application which allows the visual comparison of the results of various clustering algorithms. VICTOR can handle multiple cluster set results simultaneously and compare them using ten different metrics. Clustering results can be filtered and compared to each other with the use of data tables or interactive heatmaps, bar plots, correlation networks, sankey and circos plots. |
http://www.ncbi.nlm.nih.gov/pubmed/34525286,http://www.ncbi.nlm.nih.gov/pubmed/30053014,http://www.ncbi.nlm.nih.gov/pubmed/28976850 | What is GLS-5700? | GLS-5700 is a synthetic, consensus DNA vaccine encoding the ZIKV premembrane and envelope proteins that was tested for Zika virus disease. |
http://www.ncbi.nlm.nih.gov/pubmed/32647372,http://www.ncbi.nlm.nih.gov/pubmed/33155136,http://www.ncbi.nlm.nih.gov/pubmed/32826850 | Is histone variant H3.3K27M associated with gliomas? | Yes,
Diffuse intrinsic pontine gliomas (DIPG) are the most aggressive brain tumors in children with 5-year survival rates of only 2%. About 85% of all DIPG are characterized by a lysine-to-methionine substitution in histone 3, which leads to global H3K27 hypomethylation accompanied by H3K27 hyperacetylation. |
http://www.ncbi.nlm.nih.gov/pubmed/9848072,http://www.ncbi.nlm.nih.gov/pubmed/31513041,http://www.ncbi.nlm.nih.gov/pubmed/23868667,http://www.ncbi.nlm.nih.gov/pubmed/14991311,http://www.ncbi.nlm.nih.gov/pubmed/12165712,http://www.ncbi.nlm.nih.gov/pubmed/30845834,http://www.ncbi.nlm.nih.gov/pubmed/31478935,http://www.ncbi.nlm.nih.gov/pubmed/11316017,http://www.ncbi.nlm.nih.gov/pubmed/23960918,http://www.ncbi.nlm.nih.gov/pubmed/20398107,http://www.ncbi.nlm.nih.gov/pubmed/22496438,http://www.ncbi.nlm.nih.gov/pubmed/23112265 | What is another name for keratomileusis? | Report the outcomes of laser in situ keratomileusis (LASIK) for high myopia correction after long-term follow-up['Report the outcomes of laser in situ keratomileusis (LASIK) for high myopia correction after long-term follow-up.']Laser in situ keratomileusis is also known as LASIKLaser in situ keratomileusis (LASIK) |
http://www.ncbi.nlm.nih.gov/pubmed/32589708 | In which motif of the RUNX1T1 protein is the rs34269950 SNP located? | The rs34269950 SNP of RUNX1T1 is located in the 'RRACH' motif. |
http://www.ncbi.nlm.nih.gov/pubmed/33308444 | What is caused by SCUBE3 loss of function? | SCUBE3 loss-of-function causes a recognizable recessive developmental disorder due to defective bone morphogenetic protein signaling.SCUBE3 is a BMP2/BMP4 co-receptor. It is responsible for the development of bone and teeth. When it is not functioning properly, it inhibits the growth and development of these tissues.SCUBE3 loss-of-function results in a human disease caused by defective function of a member of the SCUBE family that is associated with a previously unrecognized syndromic disorder. The disorder is characterized by reduced growth, skeletal features, distinctive craniofacial appearance, and dental anomalies. It is also associated with dysregulating bone morphogenetic protein signaling. |
http://www.ncbi.nlm.nih.gov/pubmed/33023657,http://www.ncbi.nlm.nih.gov/pubmed/19949897,http://www.ncbi.nlm.nih.gov/pubmed/20643620,http://www.ncbi.nlm.nih.gov/pubmed/31254462,http://www.ncbi.nlm.nih.gov/pubmed/33790157,http://www.ncbi.nlm.nih.gov/pubmed/17079693,http://www.ncbi.nlm.nih.gov/pubmed/32399998,http://www.ncbi.nlm.nih.gov/pubmed/28174487,http://www.ncbi.nlm.nih.gov/pubmed/33144447,http://www.ncbi.nlm.nih.gov/pubmed/27330345,http://www.ncbi.nlm.nih.gov/pubmed/31832229,http://www.ncbi.nlm.nih.gov/pubmed/32588749,http://www.ncbi.nlm.nih.gov/pubmed/32053133,http://www.ncbi.nlm.nih.gov/pubmed/21063416,http://www.ncbi.nlm.nih.gov/pubmed/30248163,http://www.ncbi.nlm.nih.gov/pubmed/33977607,http://www.ncbi.nlm.nih.gov/pubmed/32994804,http://www.ncbi.nlm.nih.gov/pubmed/17653254,http://www.ncbi.nlm.nih.gov/pubmed/29802221,http://www.ncbi.nlm.nih.gov/pubmed/32156916,http://www.ncbi.nlm.nih.gov/pubmed/18544957,http://www.ncbi.nlm.nih.gov/pubmed/34877325,http://www.ncbi.nlm.nih.gov/pubmed/33215454,http://www.ncbi.nlm.nih.gov/pubmed/21300933,http://www.ncbi.nlm.nih.gov/pubmed/17548840,http://www.ncbi.nlm.nih.gov/pubmed/18361802,http://www.ncbi.nlm.nih.gov/pubmed/29423680,http://www.ncbi.nlm.nih.gov/pubmed/33340853 | Which drugs are included in the CAPOX chemotherapy regimen for colorectal cancer? | CAPOX chemotherapy regimen for colorectal cancer includes capecitabine plus oxaliplatin. |
http://www.ncbi.nlm.nih.gov/pubmed/32612187,http://www.ncbi.nlm.nih.gov/pubmed/33184939,http://www.ncbi.nlm.nih.gov/pubmed/30483787 | Is FKBP52 encoding a chaperone ? | Yes,
FKBP52 is a co-chaperone. |
http://www.ncbi.nlm.nih.gov/pubmed/21112347,http://www.ncbi.nlm.nih.gov/pubmed/32071244,http://www.ncbi.nlm.nih.gov/pubmed/28927876,http://www.ncbi.nlm.nih.gov/pubmed/26064593,http://www.ncbi.nlm.nih.gov/pubmed/33141148,http://www.ncbi.nlm.nih.gov/pubmed/16691572,http://www.ncbi.nlm.nih.gov/pubmed/21104292,http://www.ncbi.nlm.nih.gov/pubmed/32303866,http://www.ncbi.nlm.nih.gov/pubmed/18366747 | Isotocin is an homolog of what hormone? | Isotocin is a homolog of oxytocin. |
http://www.ncbi.nlm.nih.gov/pubmed/30776422 | Fingolimod is a selective antagonist for which molecule? | Fingolimod is a selective S1P1 functional antagonist by induction of irreversible S1P1 internalization and degradation. |
http://www.ncbi.nlm.nih.gov/pubmed/29501724 | Does αCGRP have amyloidogenic properties? | Yes. αCGRP, a 37-residue-long peptide hormone, is a novel amyloidogenic member of the CGRP familyYes, it has amyloidogenic properties. It is a member of the CGRP family. |